Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization

Experimental Neurology

Volumn 182, Issue 2, 2003, Pages 322-334

  Perez Torres S ^a   Cortes R ^a   Tolnay, M ^b   Probst, A ^b   Palacios, J M ^c   Mengod, G ^a  

^a INST D INVESTIGACIONS B   (Spain)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Almirall Prodesfarma SA ^*  (Spain)

Author keywords

Alzheimer's disease, Braak stage; cAMP signaling; mRNA localization; PDE7A; PDE7B; PDE8B

Indexed keywords

CYCLIC AMP; ISOENZYME; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 8; PHOSPHODIESTERASE VII; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CELL POPULATION; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NERVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 0041695221     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00042-6     Document Type: Article

References (58)

1. Albretsen C., Haukanes B.I., Aasland R., Kleppe K. Optimal conditions for hybridization with oligonucleotides a study with myconcogene DNA probes . Anal. Biochem. 170:1988;193-202.
2. Barnes M.J., Cooper N., Davenport R.J., Dyke H.J., Galleway F.P., Galvin F.C., Gowers L., Haughan A.F., Lowe C., Meissner J.W., Montana J.G., Morgan T., Picken C.L., Watson R.J. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg. Med. Chem. Lett. 11:2001;1081-1083.
3. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., Kagey-Sobotka A., Torphy T.J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor in vitro anti-inflammatory actions . J. Pharmacol. Exp. Ther. 284:1998;420-426.
4. 3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 818:1999;383-396.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.). 82:1991;239-259.
6. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 18:1997;351-357.
7. Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl. 53:1998;127-140.
8. Braak H., Braak E., Bohl J., Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J. Neural Transm. Suppl. 54:1998;97-106.
9. Brenner M., Lampel K., Nakatani Y., Mill J., Banner C., Mearow K., Dohadwala M., Lipsky R., Freese E. Characterization of human cDNA and genomic clones for glial fibrillary acidic protein. Mol. Brain Res. 7:1990;277-286.
10. Brun A., Englund E. A white matter disorder in dementia of the Alzheimer type a pathoanatomical study . Ann. Neurol. 19:1986;253-262.
11. Bundschuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297:2001;280-290.
12. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1999;1-38.
13. Cowburn R.F., Fowler C.J., O'Neill C. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurol. Scand. Suppl. 165:1996;25-32.
14. Falcon J., Gaildrat P. Variations in cyclic adenosine 3′,5′-monophosphate and cyclic guanosine 3′,5′-monophosphate content and efflux from the photosensitive pineal organ of the pike in culture. Pflugers Arch. 433:1997;336-342.
15. Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I., Soderling S., Hetman J., Beavo J.A., Phillips S.C. Molecular cloning and characterization of a distinct human phosphodiesterase gene family PDE11A . Proc. Natl. Acad. Sci. USA. 97:2000;3702-3707.
16. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 246:1998;570-577.
17. Folcik V.A., Smith T., O'Bryant S., Kawczak J.A., Zhu B., Sakurai H., Kajiwara A., Staddon J.M., Glabinski A., Chernosky A.L., Tani M., Johnson J.M., Tuohy V.K., Rubin L.L., Ransohoff R.M. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors . J. Neuroimmunol. 97:1999;119-128.
18. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 19:1971;1-8.
19. 3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 850:1999;104-117.
20. Gardner C., Robas N., Cawkill D., Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 272:2000;186-192.
21. Giembycz M.A., Dent G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy. 22:1992;337-344.
22. Glavas N.A., Ostenson C., Schaefer J.B., Vasta V., Beavo J.A. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA. 98:2001;6319-6324.
23. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease the potential role of a "cytokine cycle" in disease progression . Brain Pathol. 8:1998;65-72.
24. Griswold D.E., Webb E.F., Breton J., White J.R., Marshall P.J., Torphy T.J. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation. 17:1993;333-344.
25. Gurr E. Biological Staining Methods. 8th ed:1973;Saearle Diagnostic, Buckinghamshire, England.
26. Han P., Zhu X., Michaeli T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. 272:1997;16152-16157.
27. Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S., Kawarada Y., Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250:1998;751-756.
28. Hetman J.M., Soderling S.H., Glavas N.A., Beavo J.A. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. USA. 97:2000;472-476.
29. Horowski R., Sastre-y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients global evaluation of the preliminary reports . Curr. Ther. Res. 38:1985;23-29.
30. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 69:2001;249-315.
31. Houslay M.D., Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 22:1997;217-224.
32. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions . Adv. Pharmacol. 44:1998;225-342.
33. Karnovsky M.J., Root L. A direct coloring thiocholine method for cholinesterase. J. Histochem. Cytochem. 12:1964;219-221.
34. Li L., Yee C., Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 283:1999;848-851.
35. Martinez A., Castro A., Gil C., Miralpeix M., Segarra V., Domenech T., Beleta J., Palacios J.M., Ryder H., Miro X., Bonet C., Casacuberta J.M., Azorin F., Pina B., Puigdomenech P. Benzyl derivatives of 2,1,3-benzo-and benzothieno[3,2-a]thiadiazine 2,2-dioxides first phosphodiesterase 7 inhibitors . J. Med. Chem. 43:2000;683-689.
36. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 335:1990;1037.
37. McGeer P.L., McGeer E.G. The inflammatory response system of brain implications for therapy of Alzheimer and other neurodegenerative diseases . Brain Res. Rev. 21:1995;195-218.
38. McGeer P.L., Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 42:1992;447-449.
39. Michaeli T., Bloom T.J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J.A., Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268:1993;12925-12932.
40. Miró X., Casacuberta J.M., Gutierrez-López M.D., de Landazuri M.O., Puigdomènech P. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha(1). Biochem. Biophys. Res. Commun. 274:2000;415-421.
41. Miró X., Pérez-Torres S., Palacios J.M., Puigdomènech P., Mengod G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse. 40:2001;201-214.
42. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
43. Nieuwenhyus R., Voogd J., vanHuijzen Chr. The Human Central Nervous System. third revised ed:1988;Springer-Verlag, Berlin.
44. O'Donnell J.M., Frith S. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol. Biochem. Behav. 63:1999;185-192.
45. Parent A. Carpenter's Human Neuroanatomy. 1996;Williams & Wilkins, Baltimore.
46. Paxinos G. The Human Nervous System. 1990;Academic Press, San Diego.
47. 3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 20:2000;349-374.
48. Rose S.E., Chen F., Chalk J.B., Zelaya F.O., Strugnell W.E., Benson M., Semple J., Doddrell D.M. Loss of connectivity in Alzheimer's disease an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging . J. Neurol. Neurosurg. Psychiatry. 69:2000;528-530.
49. Sasaki T., Kotera J., Yuasa K., Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 271:2000;575-583.
50. Schubert P., Morino T., Miyazaki H., Ogata T., Nakamura Y., Marchini C., Ferroni F. Cascading glia reactions a common pathomechanism and its differentiated control by cyclic nucleotide signaling . Ann. N. Y. Acad. Sci. 903:2000;24-33.
51. Schubert P., Ogata T., Marchini C., Ferroni S. Glia-related pathomechanisms in Alzheimer's disease a therapeutic target? Mech. Ageing Dev. 123:2001;47-57.
52. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron. 6:1991;487-498.
53. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling new phosphodiesterases and new functions . Curr. Opin. Cell Biol. 12:2000;174-179.
54. Souness J.E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 47:2000;127-162.
55. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 62:1994;1039-1047.
56. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18:1997;164-171.
57. Toward T.J., Broadley K.J. Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs effect of rolipram and dexamethasone . J. Pharmacol. Exp. Ther. 298:2001;298-306.
58. Wang P., Wu P., Egan R.W., Billah M.M. Human phosphodiesterase 8A splice variants cloning, gene organization, and tissue distribution . Gene. 280:2001;183-194.